Core Viewpoint - Organigram Global Inc. has received a recommendation from Institutional Shareholder Services Inc. (ISS) for shareholders to vote in favor of the acquisition of Sanity Group GmbH, citing strong strategic rationale and institutional confidence in the transaction [1][3]. Acquisition Details - The acquisition involves a combination of cash and Organigram shares valued at C$3.00 per share for Sanity shareholders, representing a 71.4% premium over the last unaffected trading price [4]. - The total upfront consideration for the acquisition is €113.4 million, consisting of €80.0 million in cash and €33.4 million in Organigram shares, with potential contingent earn-out consideration of up to €113.8 million based on Sanity's financial performance post-closing [4]. Strategic Rationale - ISS highlighted that the acquisition will provide increased scale, geographic diversification, improved market presence, a stronger balance sheet, and enhanced cash flow generation for the combined company [3]. - The transaction is supported by a private placement financing from British American Tobacco, Organigram's largest shareholder, indicating strong institutional confidence [3]. Market Reaction - Following the announcement, Organigram's shares experienced a positive market reaction, outperforming both the S&P/TSX Composite Index and the S&P/TSX Composite Pharmaceuticals Index [10]. - ISS noted that the favorable market reaction suggests elevated risk if the transaction is not approved [10]. Board Support - The Board of Directors of Organigram unanimously recommends that shareholders vote in favor of the transaction, having consulted with financial and legal advisors and received a fairness opinion confirming the financial fairness of the deal [5][10]. Meeting Matters - In addition to the acquisition vote, shareholders will also vote on the election of ten director nominees, the appointment of PricewaterhouseCoopers LLP as auditor, and the re-approval of unallocated awards under the Omnibus Equity Incentive Plan, with the Board recommending support for all these matters [6].

Core Insights - Curaleaf Holdings, Inc. has announced a binding commitment to acquire The Cannabist Company's Virginia assets, which include a cultivation facility and five retail dispensaries, with plans to open one additional dispensary [1] - The transaction is expected to close in the first quarter of 2026, pending the fulfillment of closing conditions [1] - A 15 business day go-shop period is in place, ending on December 22, 2025, during which competing bids can be accepted [1] - If a competing bid is accepted or if The Cannabist fails to secure noteholder consent, Curaleaf will receive a break-up fee of $3.3 million and associated expenses up to $350,000 [1] Company Overview - Curaleaf is a leading international provider of consumer cannabis products, focusing on enhancing lives through the power of the plant [2] - The company operates under various brands, including Curaleaf, Select, Grassroots, Find, Anthem, and The Hemp Company, and is known for quality and reliability in the cannabis market [2] - Curaleaf has a strong presence across the supply chain and operates a unique distribution network in Europe, Canada, and Australasia [2]